Survey
* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project
Download 2007 to present - Vanderbilt
Document related concepts
no text concepts found
Transcript
2007 August 14 Paul Mischel, MD, PhD Departments of Pathology & Lab Medicine and Molecular & Med Pharmacology, UCLA School of Medicine Molecularly targeted therapy of glioblastoma: Implications for clinical development across tumor types August 23 Claire Dees, MD Lineberger Cancer Center, University of North Carolina at Chapel Hill Novel targeted therapies for breast cancer October 9 Donna J. Webb, PhD Department of Biological Sciences, Vanderbilt University Cancer cell migration: Signaling pathways that regulate adhesion and cytoskeletal dynamics October 11 Mark E. Burkard, MD, PhD Memorial Sloan-Kettering Cancer Center Using chemical genetics to probe the function of a cancer kinase November 6 Alisa Weaver, MD, PhD Department of Cancer Biology, Vanderbilt University Regulation of the mammary epithelial phenotype by WAVE-2 December 11 Wael El-Rifai, PhD, MD Departments of Surgery and Cancer Biology, Vanderbilt University Revisiting the genes in the ErbB2 amplicon: Implications for breast cancer 2008 January 17 Carey Anders, MD Duke University Medical Center Accelerating therapeutics options for patients with breast cancer-related brain metastases February 19 Ruth O’Regan, MD Winship Cancer Institute, Emory University Optimizing therapies for breast cancer subtypes February 26 Andries Ziljstra, PhD Department of Pathology, Vanderbilt University The role of cell migration in metastasis April 1 Tan A. Ince, MD, PhD Department of Pathology, Brigham & Women’s Hospital, Harvard Medical School Breast cancer cell-of-origin and tumor phenotype April 8 Wei Zheng, PhD, MD, MPH Vanderbilt Epidemiology Center and Institute for Medicine and Public Health Breast cancer genetics: From candidate gene studies to genome-wide association scans April 10 Nancy E. Davidson, MD Sidney Kimmel Cancer Center, Johns Hopkins School of Medicine Exploiting epigenetic alterations in breast cancer April 24 Joyce Slingerland, MD, PhD University of Miami Sylvester Cancer Center The role of Src in human breast cancer progression May 3 Lynn C. Hartmann, MD Women’s Cancer Program, Mayo Clinic Cancer Center Risk prediction strategies for breast cancer May 22 Ramon Parsons, MD, PhD Herbert Irving Comp. Cancer Center, Columbia University Analysis of PTEN and PI3 kinase in breast cancer June 10 Yibin Kang, PhD Department of Molecular Biology, Princeton University Functional genomics of breast cancer metastases June 16 Vandana Abramson, MD Department of Hematology-Oncology, University of Pennsylvania Molecular therapeutic targets in two early-phase clinical trials July 1 Fraser Symmans, MD Department of Pathology, MD Anderson Cancer Center Development and and clinical implementation of pharmacogenomic predictors for treatment of breast cancer August 5 Levi Garraway, MD, PhD Broad Institute/MIT, Dana-Farber Cancer Institute, Harvard Medical School Oncogenic signaling downstream of activated phosphatidylinositol-3 (PI3) kinase August 14 Andrea Richardson, MD, PhD Department of Pathology, Brigham & Women’s Hospital, Harvard Medical School Basal-like breast cancer: How should we define it and how do we defeat it? October 21 Jin Chen, PhD, MD Departments of Medicine and Cancer Biology, Vanderbilt University Role of EphA2 receptor tyrosine kinase in tumor resistance to HER2 inhibitors November 18 Breast Cancer SPORE Advocates Vanderbilt-Ingram Cancer Center The Evolving Role of Research Advocacy: VICC Advocates at the NCI Translational Science Meeting 2009 December 9 Albert B. Reynolds, PhD Department of Cancer Biology, Vanderbilt University Effects of p120 knockout in normal and middle T oncogene-transformed mammary glands January 12 Kwok-Kin Wong, MD, PhD Dana-Farber Cancer Institute, Harvard Medical School Use of genetically engineered cancer mouse models for preclinical testing of novel therapeutics March 10 Rebecca S. Cook, PhD Department of Cancer Biology, Vanderbilt University Role of ErbB3/HER3 in mammary gland development and cancer progression April 14 Ambra Pozzi, PhD Departments of Medicine and Cancer Biology, Vanderbilt University The role of collagen binding receptors in tumorigenesis July 14 Ralf Landgraf, PhD Departments of Biochemistry and Molecular Biology, U of Miami Miller School of Medicine ERBB2/ERBB3 activation as a spatially and mechanistically multilayered event August 11 Sharat Singh, PhD Prometheus Laboratories Array-based detection of signaling pathways in circulating tumor cells and fine needle aspirates using collaborative proximity immunoassay (COPIA) August 13 Raghu Kalluri, MD, PhD Departments of Biological Chemistry and Molecular Pharmacology, Beth Israel Deaconess Medical Center, Harvard Medical School Diverse role of mesenchymal cells in cancer progression and metastasis August 16 Mien-Chie Hung, Ph.D. Department of Molecular and Cellular Oncology, MD Anderson Cancer Center Novel signaling in cancer cells and development of targeted therapy September 1 Matthew Goetz, MD Departments of Oncology and Pharmacology; Mayo College of Medicine and Mayo Clinic Cancer Center Tamoxifen and CYP2D6: Using pharmacogenetics to discover a new drug September 8 Mia Levy, MD, PhD Departments of Biomedical Informatics and Medicine, Vanderbilt University Systems to support treatment response assessment: Applications to breast cancer November 24 Neal Rosen, MD, PhD Department of Medicine, Program in Molecular Pharmacology, Memorial Sloan-Kettering Cancer Ctr Inhibition of Ras and PI3K pathways in human cancer: Basic mechanisms and clinical implications 2010 January 19 Linda Sealy, PhD Department of Molecular Physiology & Biophysics, Vanderbilt University The role of C/EBP in Ras transformation: What’s myth, remarkable and missing March 3 David Gius, MD, PhD Departments of Radiation Oncology and Pediatrics, Vanderbilt University Loss of SIRT3, a mithocondria-localized tumor suppressor, results in ER-positive mammary tumors March 31 Jennifer A. Pietenpol, PhD Department of Biochemistry, Vanderbilt-Ingram Cancer Center, Vanderbilt University Molecular subtypes and therapeutic target discovery in triple negative breast cancer July 27 Dominique Delbeke, MD, PhD Department of Radiology & Radiological Sciences, Vanderbilt University Molecular Imaging with PET and SPECT for Clinical Investigation in Breast Cancer August 31 Stephen Fesik, PhD Departments of Biochemistry, Pharmacology, and Chemistry, Vanderbilt University Development of MYC inhibitors using a fragment based structural approach September 14 Carlos L. Arteaga, MD Departments of Medicine and Cancer Biology, Vanderbilt University Role of ErbB3 in oncogene-induced transformation and drug resistance: Clinical implications November 9 Melissa Skala, PhD Department of Biomedical Engineering, Vanderbilt University Multi-functional optical imaging of cancer in pre-clinical models November 16 Ben Ho Park, MD, PhD Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine Exploiting breast cancer genetics for diagnostics and therapy 2011 March 8 Robert Schneider, PhD Departments of Microbiology and Radiation Oncology, New York University Translating translational control to therapy in advanced breast cancer April 12 Suzanne Conzen, MD Department of Medicine, University of Chicago An unexpected role for glucocorticoid receptor signaling in breast cancer May 9 Forest M. White, PhD Department of Biological Engineering, Massachusetts Institute of Technology Characterization of regulatory signaling nodes in human mammary epithelial cells through quantitative phosphoproteomic analysis June 14 Ann W. Richmond, PhD Department of Cancer Biology, Vanderbilt University Chemokine receptor modulation of breast cancer metastasis July 12 Thomas Westbrook, PhD Departments of Molecular & Human Genetics and Biochemistry & Molecular Biology Baylor College of Medicine Tackling breast cancer: From genetic screens to new therapeutic strategies August 25 Ross Camidge, MD, PhD Department of Medicine and Thoracic Oncology Program, University of Colorado Cancer Center Getting it right from the start in drug development: Evolved September 13 Jeffrey A. Engelman, MD, PhD Thoracic Oncology Program, Massachusetts General Hospital Cancer Center, Harvard Medical School Overcoming intrinsic and acquired resistance to targeted therapies October 11 Mary M. Zutter, MD Departments of Pathology, Microbiology & Immunology, and Cancer Biology, Vanderbilt University The 21 integrin: A metastasis suppressor in breast and prostate cancer December 13 Samuel Waxman, MD Department of Hematology & Medical Oncology, Mount Sinai Cancer Center Targeted epigenetic therapy of triple negative breast cancer 2012 February 13 Harold L. Moses, MD Departments of Cancer Biology, and Pathology, Microbiology & Immunology, Vanderbilt University The TGF pathway in breast cancer: Role as a tumor suppressor and tumor promoter April 10 Jonathan M. Irish, PhD Department of Cancer Biology, Vanderbilt University Translational flow cytometry and single cell systems biology April 23 Ethan Lee, MD, PhD Department of Cell & Developmental Biology, Vanderbilt University Mechanisms of Wnt signaling: Implications for cancer therapeutics April 30 Pepper Schedin, PhD Department of Medicine, University of Colorado Mammary stroma as an NSAID target: Implications for pregnancy-associated breast cancer June 12 Andrei Goga, MD, PhD Department of Medicine, University of California at San Francisco Targeting the MYC pathway in cancer July 3 Eric Knudsen, PhD Department of Cancer Biology Kimmel Cancer Center, Thomas Jefferson University Rationally targeting tumor suppressor pathway dysfunction in breast cancer July 17 Andrea Califano, PhD Departments of Biochemistry & Molecular Biophysics and Biomedical Informatics Institute of Cancer Genetics, Herbert Irving Cancer Center at Columbia University Interrogating regulatory networks to discover master regulators of tumor initiation, progression and drug sensitivity August 1 Charles M. Perou, PhD Departments of Genetics and Pathology Lineberger Comprehensive Cancer Center, University of North Carolina Tumor subtypes and personalized genetics for breast cancer patients August 27 Rebecca S. Cook, PhD Department of Cancer Biology, Vanderbilt University ErbB family receptor tyrosine kinases: At the interface of breast development and cancer September 4 Edward Chekmenev, PhD Department of Radiology & Radiological Sciences Vanderbilt University Institute of Imaging Sciences Molecular imaging of breast cancer using hyperpolarized MRI contrast agents November 5 Deborah A. Lannigan, PhD Department of Pathology, Microbiology & Immunology, Vanderbilt University ERK1/2-RSK signaling in breast development and cancer November 27 Carlos López, PhD Department of Cancer Biology, Vanderbilt University Programming biological models to explore mechanistic hypotheses in apoptosis signaling 2013 January 15 Ian G. Macara, PhD Department of Cell and Developmental Biology, Vanderbilt University ‘Cell Polarity, Stem Cells and Metastasis’ January 22 Sheri Wilcox, PhD and Preston Hensley, PhD SomaLogic, Inc. ‘Unlocking protein biomarkers with SOMAmers: Novel protein affinity reagents measuring >1000 analytes’ February 11 David Piwnica-Worms, MD, PhD Bright Institute and Molecular Imaging Center Washington University School of Medicine ‘Cancer Genomics and Systems Heterogeneity: Characterization and Challenges’ March 12 Thomas Stricker, MD, PhD Center for Advanced Laboratory Diagnostics Department of Pathology, Microbiology & Immunology, Vanderbilt University ‘The Translational Landscape of Breast Cancer’ April 1 Georgia Weisner, MD Clinical and Translational Hereditary Cancer Program Division of Genetic Medicine, Vanderbilt University ‘Cancer Genetics: From Gene Discovery to Cancer Care’ July 8 Cyril H. Benes, PhD Director, Center for Molecular Therapeutics Massachusetts General Hospital Cancer Center ‘Functionalizing Cancer Genomes by High-Throughput Cell Line Screening’ August 20 Ben Ho Park, MD, PhD Associate Professor of Oncology Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins ‘Circulating plasma tumor DNA biomarkers to guide systemic therapy decisions in breast oncology’ October 1 Atul Bedi, MD Associate Professor of Oncology Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins ‘Bifunctional Immunostimulatory Antibodies for Targeted Immunotherapy of Cancer’ October 8 Paul Workman, PhD Deputy Chief Executive and Head, Division of Cancer Therapeutics Director, Cancer Research UK Cancer Therapeutics Unit, Institute of Cancer Research ‘Challenges to Personalized Medicine Exemplified by PI-3 Kinase and HSP90 Inhibitors’ October 29 Nikhil Wagle, MD Dana Farber Cancer Institute and Harvard Medical School ‘Clinical and Translational Cancer Genomics in Cancer’ November 25 Alana Welm, PhD Department of Oncological Sciences University of Utah School of Medicine ‘New strategies to prevent and treat metastatic breast cancer using patient-derived tumor grafts’ 2014 January 7 Yibin Kang, PhD Department of Molecular Biology, Princeton University ‘Molecular circuitry and targeting opportunities in breast cancer metastases’ January 13 Daniel B. Brown, MD Department of Radiology & Radiological Sciences, Vanderbilt University ‘Targeted oncologic therapies with imaging guidance’ February 25 Alissa Weaver, MD, PhD Department of Cancer Biology, Vanderbilt University ‘Regulation of cancer invasiveness by exosomes’ March 11 Cory M. Johannessen, PhD The Broad Institute of MIT Harvard Medical School ‘Deconstructing therapeutic resistance in the era of precision medicine’ March 12 Neal Rosen, MD, PhD Center for Mechanism-Based Cancer Therapeutics Memorial Sloan-Kettering Cancer Center ‘A unified model of RAF activation in human cancer’ May 13 Ryoma Ohi, PhD Department of Cell & Developmental Biology Vanderbilt University ‘Cell Biology and Pharmacology of the Mitotic Spindle’ July 8 Gad A. Getz, PhD Broad Institute at MIT and Mass General Hospital Cancer Center Department of Pathology, Harvard Medical School ‘Cancer Genomics and Evolution’ July 29 Robert J. Coffey, MD Departments of Medicine and Cell & Developmental Biology Vanderbilt University School of Medicine ‘From New Modes of Signaling to New Models of Cancer’ September 2 Rosalie C. Sears, PhD Department of Molecular and Medical Genetics Oregon Health & Science University ‘Tumor cell heterogeneity and therapeutic response in breast cancer’ September 16 Jeffrey Settleman, PhD Senior Director, Discovery Oncology Genentech, Inc. ‘Overcoming resistance to anti-cancer drugs’ 2015 January 12 Maurizio Scaltriti, PhD Human Oncology & Pathogenesis Program Memorial Sloan-Kettering Cancer Center ‘Rationale-based therapeutic combinations with PI3K/AKT inhibitors’ March 17 William P. Tansey, PhD Department of Cell & Developmental Biology Vanderbilt University School of Medicine ‘MYC and chromatin’ June 9 Ken S. Lau, PhD Department of Cell & Developmental Biology Vanderbilt University School of Medicine ‘Next-Gen Pathology: Using Network Medicine to Dissect Epithelial Tissue Heterogeneity’ June 23 Dana Brantley-Sieders, PhD Departments of Medicine and Cancer Biology Vanderbilt University School of Medicine ‘Role of EphA2 receptor tyrosine kinase in triple-negative/basal-like breast cancer July 7 Thomas E. Yankeelov, PhD Department of Radiology & Radiological Sciences Vanderbilt University Institute of Imaging Science ‘Quantitative MRI of breast cancer treatment response’ December 1 Howland E. Crosswell, MD Chief Medical Officer, KIYATEC, Inc. ‘Ex-vivo 3D functional drug response profiling in breast and ovarian cancer’ 2016 February 2 Sarat Chandarlapaty, MD, PhD Human Oncology Pathogenesis Program Memorial Sloan Kettering Cancer Center ‘Hormone refractory breast cancer: Mechanisms of reactivation of ER signaling and consequences for therapy’
Related documents